Median total new lesion volume

Slides:

Advertisements

Similar presentations

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..

Advertisements

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Transcatheter versus Surgical Aortic Valve Replacement Objective:to assess the clinical outcomes of transcatheter versus surgical aortic valve replacement.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

G. Michael Deeb, MD On Behalf of the CoreValve US Investigators

TAVR in Patients With Chronic Kidney Disease

(p for noninferiority = 0.01)

TriGuard Device for Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Multicenter Real-World Experience Masieh Abawi, Ermela.

Trans- catheter aortic valve replacement vs

Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.

Late breaking news in heart valve disease

Eric Van Belle MD-PhD, Nicolas Debry MD et al. Heart Institute

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis Ashok.

CRT 2017: Putting LAA closure in the age of DOACs into perspective

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

Heart Valve Thrombosis & Neuro-Outcomes

Claret Cerebral Protection Device: Implications of the Sentinel Study

Copyright © 2014 American Medical Association. All rights reserved.

5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

The Ever-Expanding Patient Pool for TAVR:

Nat. Rev. Cardiol. doi: /nrcardio

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

Angiography-guided PCI

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Losartan vs. Atenolol in Marfan Syndrome

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.

How to Optimize TAVR Outcomes

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

Nat. Rev. Cardiol. doi: /nrcardio

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Total lesions on MRI at 48 hours

Nat. Rev. Cardiol. doi: /nrcardio

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

(p < for noninferiority)

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Mancini JG, et al. Am J Cardiol.

Miralem Pasic et al. JCIN 2015;8:1-9

(p = for noninferiority)

The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement Thomas.

Nicolaj C. Hansson et al. JACC 2016;68:

Simultaneous transapical transcatheter aortic and mitral valve replacement in a high-risk patient with a previous mitral bioprosthesis Adil H. Al Kindi,

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

Michele Gallo, MD, Gino Gerosa, MD

Baseline Clinical Characteristics

Nat. Rev. Cardiol. doi: /nrcardio

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

MATRIX: Radial vs. Femoral

Commentary: When a choice is not an echo

Sung-Han Yoon et al. JACC 2017;69:

An ancillary study to the ARCADIA trial

Stefan Toggweiler et al. JCIN 2016;9:

Presentation transcript:

Median total new lesion volume SENTINEL Trial design: High-risk patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) were randomized in a 2:1 ratio to embolic protection with the Sentinel device or routine care. They were followed for 30 days. Results (p = 0.33) Median total new lesion volume at day 2-7: Sentinel vs. control: 102.8 vs. 178.0 mm3, p = 0.33. Total new lesion volume: 294 vs. 309.8 mm3, p = 0.81 Major vascular complication: 8.6% vs. 5.9%, p = 0.53 30-day MACCE: 7.3% vs. 9.9%, p = 0.4; mortality: 1.3% vs. 1.8%, p = 0.65; all strokes: 5.6% vs. 9.1%, p = 0.25; disabling stroke: 0.9% vs. 0.9%, p = 1.0 mm3 Conclusions Routine use of the Sentinel device did not result in reduction in new lesion volume on MRI or strokes within 30 days compared with routine care in patients undergoing TAVR Adds to the total procedure and fluoroscopic times with a slight increase in vascular complication rates Median total new lesion volume Sentinel (n = 244) Control (n = 119) Kapadia SR, et al. J Am Coll Cardiol 2016;Nov 1:[Epub]